Ingevity (NYSE:NGVT) Updates FY 2026 Earnings Guidance

Ingevity (NYSE:NGVT) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.800-5.20 for the period, compared to the consensus earnings per share estimate of 4.760. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Ingevity Stock Performance

NGVT traded down $1.25 during midday trading on Wednesday, reaching $69.87. The company’s stock had a trading volume of 395,125 shares, compared to its average volume of 302,217. Ingevity has a twelve month low of $28.49 and a twelve month high of $77.46. The stock has a market cap of $2.51 billion, a P/E ratio of -38.39 and a beta of 1.34. The company has a fifty day simple moving average of $66.52 and a 200 day simple moving average of $58.83. The company has a current ratio of 1.27, a quick ratio of 0.80 and a debt-to-equity ratio of 8.39.

Wall Street Analyst Weigh In

NGVT has been the subject of several research reports. Zacks Research upgraded shares of Ingevity to a “hold” rating in a research note on Tuesday, December 16th. BMO Capital Markets raised their price objective on Ingevity from $64.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Wells Fargo & Company lifted their price objective on Ingevity from $60.00 to $65.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $67.50.

Institutional Investors Weigh In On Ingevity

Several large investors have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new position in Ingevity during the 4th quarter worth $27,000. Meeder Asset Management Inc. acquired a new stake in shares of Ingevity in the 4th quarter valued at $33,000. Geneos Wealth Management Inc. raised its position in shares of Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after acquiring an additional 387 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Ingevity during the second quarter valued at $46,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of Ingevity during the fourth quarter valued at $47,000. Institutional investors own 91.59% of the company’s stock.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.